(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/078881 A2

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01) *C07K 16/30* (2006.01)

(21) International Application Number:
PCT/IB2024/000570

(22) International Filing Date:
11 October 2024 (11.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2023-0136955 13 October 2023 (13.10.2023) KR
10-2024-0035926 14 March 2024 (14.03.2024) KR

(71) Applicants: **LIGACHEM BIOSCIENCES INC.** [KR/KR]; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **LEGOCHEM BIOSCIENCES INC.** [KR/KR]; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR).

(72) Inventors: **JANG, Tae Ik**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **PARK, Chang Sik**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **BAEK, Eun Ji**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **SONG, Ho Young**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **CHAE, Sang Eun**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **PARK, Se Yeon**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR). **CHUNG, Chul-Woong**; 10, Gukjegwahak 10-ro, Yuseong-gu, Daejeon 34002 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2025/078881 A2

(54) Title: ANTI-CLAUDIN 18.2 ANTIBODY DRUG CONJUGATES COMPRISING TOPOISOMERASE I INHIBITOR AND USES THEREOF

(57) Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) targeting human Claudin 18 isoform 2 (CLDN 18.2) and use thereof, and more particularly, to an ADC including an antibody or antigen-binding fragment thereof that binds to human CLDN18.2, and a topoisomerase I inhibitor (e.g., a camptothecin); and use of ADCs for the treatment and/or treatment of diseases, more particularly, hyperproliferative and/or angiogenic diseases, such as cancer diseases.